Supplier sign in
Home
STAY INFORMED
Subscribe to our monthly newsletter.
Your email address will never be disclosed to any third party.
Read our privacy notice.

     

COMPANY PAGE

Login
Latest update: 12-06-2019
Xtalks Life Science Webinars
Contact
Gain knowledge and stay up-to-date with the latest industry developments. Join your community to view webinars, earn points, share discussions, articles, and more.
Products, services
 Life Science - Webinars
 Food Industry - Food articles
 Medical Devices - Medical device webinars
 News - Life science news
 Blogs - food blogs
 Videos - webinar videos
Resources
Diagnostics & Life Sciences - Next generation sequencing
Diagnostics & Life Sciences - Peptide/proteine sequencers
Diagnostics & Life Sciences - DNA testing - Noninvasive prenatal testing
Diagnostics & Life Sciences - Drug development - Molecular targets and cancer therapeutics
Diagnostics & Life Sciences - Drug development - Synthetic Biology
Show more
Resources
Diagnostics & Life Sciences - Next generation sequencing
Diagnostics & Life Sciences - Peptide/proteine sequencers
Diagnostics & Life Sciences - DNA testing - Noninvasive prenatal testing
Diagnostics & Life Sciences - Drug development - Molecular targets and cancer therapeutics
Diagnostics & Life Sciences - Drug development - Synthetic Biology
Diagnostics & Life Sciences - Animal research

Current events

Collaboration Beats Compromise in Combination Product Development
Combination product design and development, and the decision making surrounding these processes, is complex. Early collaborations between CDMOs and their manufacturing partners is an effective means of managing this complexity. However, the best collaborations seek to develop a common understanding of program risks, technical risks, decision-making processes, who decision-makers are, a common language for the design and development, and a common vision for the program. These collaborations work to identify potential commercial manufacturing risks, and then address them during product development, to reduce overall risk during product launch. This effort maximizes the opportunity to successfully and efficiently manufacture combination products that are compliant with FDA 21 CFR, or other relevant regulatory standards, including 210/211 for drug handling. We will explore an effective collaborative model for combination design and development, and how we leverage this model to bring complex products, including combination products, to market in a timely manner, without sacrificing product quality.
11-08-2020 | Webinar | A morning | | Entry: Free (after registration)
Assessment of Potential Drug-Drug Interactions from In Vitro Experiments to PBPK Modeling
In this webinar, attendees will learn about: Assessment of potential DDIs by in vitro studies Application of the FDA guidance to DDI study design, data interpretation and modelling Understanding of fundamental theories and development strategies of PBPK models Benefits and applications of PBPK models to preclinical drug development and design of first clinical trials
11-08-2020 | Webinar | An afternoon | | Entry: Free (after registration)
What You Need to Know: Med Device UDI Submission to China
This webinar will give an introductory presentation on NMPA current status, what we have learned via testing and a Q&A session. Bring your specific questions concerning medical device registration scenarios, China NMPA data elements and requirements. The speakers will review and provide clarity on currently posted guidance and answer your questions on the differences between Fda gudid and China NMPA.
13-08-2020 | Webinar | A morning | | Entry: Free (after registration)
Show more (2)

Product news

MAXUS MEDIA
LABinsights.net LABinsights.de LABinsights.nl
SIGN UP FOR OUR NEWSLETTER
Newsletter archive
Service and contact
ContactDisclaimerPrivacyAdvertising